An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

NCT01019161 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukaemia

Interventions

DRUG: AZD1152
DRUG: C14 AZD1152

Sponsor

AstraZeneca